Christopher Jonkergouw

Promising science has the potential to combat rising antibiotic resistance—but too often, it never reaches patients due to a long and difficult development path. To change that, I co-founded Arivin Tx with three experienced, ambitious partners and now serve as CEO. I’ve helped secure over €4M in equity and non-dilutive funding to advance breakthrough therapies targeting some of the most resistant infections of our time, including Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa.